Quercetin-derived compound Tamarixetin may aid in pain therapy: Tamarixetin-based activation of the PD-1 pathway for Pain therapy: Tamarixetin (an O-methylated flavonol), a derivative of quercetin,  increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 2/September/2018, 11.57 pm

Act(os) against cancer: Pioglitazone (trade name: Actos), an anti-diabetic drug, increases the expression of tumor suppressors genes, such as  BTG2, PDCD4,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 2/August/2018, 11.40 pm
September 2, 2018
Eating dark chocolate may lower cholesterol and triglyceride levels: Chocolate-based therapy for Non-alcoholic fatty liver disease (NAFLD): Monomeric cocoa catechins, found in dark chocolate, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down-regulation of its target gene, 3/September/2018, 12.15 am
September 2, 2018
Show all

 Introduction: What they say: 

A recent study, from Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for Brain Science, Fudan University, Shanghai, China; and Department of Neurobiology, Duke University Medical Center, Durham, North Carolina, US, shows that “PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1.” This study was published, in the 22 May 2017 issue of Nature Neuroscience (one of the best journals in Neurobiology with an impact factor of 16.724+), by Prof Ji RR, Chen G, and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Quercetin-derived compound Tamarixetin may aid in pain therapy: Tamarixetin-based activation of the PD-1 pathway for Pain therapy: Tamarixetin (an O-methylated flavonol), a derivative of quercetin,  increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year. However, the work published recently, which is described below, may highlight the caveat in such an approach, as blocking PD-L1 may promote spontaneous pain and allodynia in cancer-bearing mice.

Prof. Ji has shown recently that: (1) Programmed cell death ligand-1 (PD-L1), produced by melanoma and normal neural tissues, inhibits acute and chronic pain; (2) injection of PD-L1 alleviates pain, and thereby functions as an analgesic agent; (3) Neutralization of PD-L1 or Block of PD1 promotes mechanical allodynia (hypersensitivity to pain); (4) PD1 null mice suffers from thermal and mechanical hypersensitivity; (5) PD-L1 promotes phosphorylation of SHP-1 and inhibits Sodium channels via PD-1 activation; and (6) PD-L1 inhibits nociceptive neuron excitability in dorsal root ganglion and thereby functions as a neuromodulator, suggesting that increasing the expression or the level of PD-L1/PD1 may alleviate pain and thermal and mechanical hypersensitivity.


From research findings to therapeutic opportunity:

This study suggests, first the first time, a quercetin-derived compound Tamarixetin may aid in the treatment of acute and chronic pain.

Tamarixetin, by increasing the expression of its target genes, it may increase PD-L1 levels (figs. 1-2). Thereby, it may: (a) inhibit acute and chronic pain; (b) alleviate thermal and mechanical hypersensitivity; (c) activate signal transduction cascade downstream of the PD-1 receptor; (c) phosphorylate SHP-1; (d) inhibit sodium channels and nociceptive neuron excitability. Thus, Tamarixetin or its analogs, either alone or in combination with other drugs,” may be used to attenuate short-term and long-term pain.

Figure 1.Mechanistic insights into how Tamarixetin inhibits acute and chronic pain. Tamarixetin enhances PD-L1 levels, suppresses thermal and mechanical hypersensitivity, phosphorylates SHP-1, inhibits activation of sodium channels, and alleviates nociceptive neuron excitability

Figure 2. Tamarixetin attenuates pain through induction of PDL1.

 

 

 

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $500#

Undisclosed mechanistic information: How does Tamarixetin increase the expression of PD-L1?

# Research cooperation


References:

Citation: Boominathan, L., Quercetin-derived compound Tamarixetin may aid in pain therapy: Tamarixetin-based activation of the PD-1 pathway for Pain therapy: Tamarixetin (an O-methylated flavonol), a derivative of quercetin,  increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 2/September/2018, 11.57 pm, Genome-2-Biomedicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.